BiofronteraBFRI
Market Cap: 6.31M
About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Employees: 85
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
6,268% more capital invested
Capital invested by funds: $26.2K [Q4 2023] → $1.67M (+$1.64M) [Q1 2024]
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
38% more funds holding
Funds holding: 8 [Q4 2023] → 11 (+3) [Q1 2024]
20.71% more ownership
Funds ownership: 0.62% [Q4 2023] → 21.33% (+20.71%) [Q1 2024]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for BFRI.